Apoaequorin

Other Names

AequorinComponent of aequorinRecombinant calcium binding protein

Synopsis

Apoaequorin: A Comprehensive Reference

1. Identity

Chemical and Biological Classification

Apoaequorin is a calcium-binding protein found in the luminescent jellyfish Aequorea victoria. It is a protein composed of 196 amino acids. In biochemical nomenclature it is the apoprotein (cofactor-free) form of the photoprotein aequorin; the full holoprotein, aequorin, is formed when apoaequorin combines with the small organic chromophore coelenterazine. When the natural (apo) form of the protein is conjugated with coelenterazine, the resulting protein aequorin has natural bioluminescence when exposed to calcium. The protein is assigned the UniProtKB/Swiss-Prot accession number P02592 and the product found in dietary supplements has been formally identified as "Aequorin-2." Capsules, chewable tablets, and protein powders have been found to contain this compound; Aequorin-2 is comprised of 196 amino acid residues, equivalent to apoaequorin with a propeptide of 7 amino acids.

Natural Source

Aequorea victoria, also sometimes called the crystal jelly, is a bioluminescent hydrozoan jellyfish, or hydromedusa, found off the west coast of North America. The species is best known as the source of aequorin (a photoprotein) and green fluorescent protein (GFP), two proteins involved in bioluminescence.

Commercial Preparation

The apoprotein, apoaequorin (without the prosthetic group coelenteramide), can be produced and purified through expression of the apoaequorin cDNA in Escherichia coli. Apoaequorin has since been synthesized using recombinant DNA and is used for tagging otherwise invisible proteins in biomedical research. Prevagen® (Quincy Bioscience; Madison, Wisconsin) is a widely advertised dietary supplement labeled to contain synthetically produced apoaequorin. Apoaequorin is available in tablets of 10, 20, and 40 mg under the brand name Prevagen. Apoaequorin has also appeared in chewable tablet and powdered-shake formulations.

2. Historical and Scientific Background

Discovery of Aequorin (1960s)

Apoaequorin has no history of traditional or indigenous medicinal use. Its story begins entirely within modern biomedical research. In 1961, Shimomura and Johnson isolated the protein aequorin, and its small molecule cofactor, coelenterazine, from large numbers of Aequorea jellyfish at Friday Harbor Laboratories. Osamu Shimomura began work into the bioluminescence of Aequorea in 1961. This involved the tedious harvesting of tens of thousands of jellyfish from the docks in Friday Harbor, Washington. It was determined that light could be produced from extracts with seawater, and more specifically, with calcium.

The discovery of aequorin, a bioluminescent protein isolated from the jellyfish Aequorea by Osamu Shimomura in the 1960s, marked a major advancement in calcium research. Aequorin emits light in response to calcium binding, allowing for real-time monitoring of calcium concentrations in biological samples. In 1967, Ridgeway and Ashley microinjected aequorin into single muscle fibers of barnacles, and observed transient calcium ion-dependent signals during muscle contraction. This property established aequorin as an invaluable tool in cell biology for monitoring intracellular calcium dynamics.

Nobel Prize Recognition

In 2008, Osamu Shimomura shared the Nobel Prize for Chemistry for the discovery that this jellyfish emits green light through a chemical process involving the binding of calcium with the protein aequorin. Their discoverers, Osamu Shimomura and colleagues, won the 2008 Nobel Prize in Chemistry for their work on GFP.

Cloning and Recombinant Production

Cloning and expression of the cDNA coding for aequorin was reported in Biochemical and Biophysical Research Communications in 1985. This was the first report on cloning aequorin cDNA. Prasher and colleagues were able to identify cloned apoaequorin from an extract recovered in E. coli expressing pBR322 plasmid vectors. Recombinant production of aequorin typically involves the heterologous expression of its apoprotein form, known as apoaequorin, which is subsequently reconstituted with the chromophore coelenterazine to yield the functional calcium-sensitive photoprotein.

Transition to Dietary Supplement

Recombinant apoaequorin, developed for use in research studies, was subsequently evaluated for its potential to improve memory. The basis for this use of aequorin was its calcium-binding characteristics, which resembled those of calmodulin, an intracellular protein complex that appears to play a central role in memory. Quincy Bioscience was founded to develop apoaequorin-based products that "help support brain function in aging."

3. Active Compounds and Proposed Mechanisms of Action

Calcium-Binding Activity

The sole active constituent of apoaequorin-containing supplements is apoaequorin itself. Its biochemical significance derives from its capacity to bind calcium ions. Apoaequorin, the active ingredient in Prevagen®, is a calcium-binding protein isolated from jellyfish Aequorea victoria and has been used for many years as a calcium indicator. Because calcium dysregulation is associated with aging, disruption of synaptic functions, and cell death, calcium-binding proteins have been pursued as a possible target for maintaining healthy calcium levels.

Calcium Dysregulation and Aging

Aging is associated with impaired function of several calcium-regulatory mechanisms, including calcium-binding proteins that normally support intracellular Ca²⁺ regulation. This age-related calcium-binding protein dysfunction and changes in expression lead to disrupted maintenance of intracellular Ca²⁺, thus contributing to memory decline. Other work has found that age-related cognitive deficits can be mitigated by either blocking Ca²⁺ entry into the cytosol or preventing its release from intracellular Ca²⁺ stores.

Proposed Mechanism for Cognitive Effects

Apoaequorin is said to improve mild age-related memory loss. Apoaequorin theoretically decreases brain calcium levels, which may improve memory. The theoretical model draws a parallel between apoaequorin and calmodulin, an endogenous calcium-binding protein involved in neuronal signaling. However, the critical limitation of this proposed mechanism is one of bioavailability: these findings were questioned because of the lack of evidence that apoaequorin is absorbed orally or can cross the blood-brain barrier.

Oral Bioavailability: A Fundamental Challenge

In tests that mimic digestion, 90% of apoaequorin was dissolved by stomach acid and enzymes in under 30 seconds. Current research has not demonstrated that apoaequorin can effectively cross the blood-brain barrier in significant amounts. There is little evidence that apoaequorin is absorbed orally; most proteins are broken down in the stomach and intestines to individual amino acids or short polypeptides. Because apoaequorin is a large protein, even the small amount that might survive the stomach is unlikely to cross into the bloodstream or pass through the blood-brain barrier. These digestion findings suggest that oral apoaequorin supplements probably do not reach the brain in meaningful quantities, calling into question claims of direct neurological benefits.

There is strong evidence suggesting that apoaequorin does not survive digestion in the gut or cross the blood-brain barrier, so is unlikely to have any effect on the brain. The FTC's legal complaint also asserted, based on the company's own safety studies, that "apoaequorin is rapidly digested in the stomach and broken down into amino acids and small peptides like any other dietary protein." The FTC's legal complaint took a firmer stance, asserting that the company's own safety studies "show that apoaequorin is rapidly digested in the stomach and broken down into amino acids and small peptides like any other dietary protein."

Neuroprotective Mechanism (Preclinical)

In preclinical in vitro and animal studies where apoaequorin was administered directly rather than orally, an alternative mechanism has been explored. Neuroprotection may involve a pre-conditioning-like effect, whereby an AQ infusion modulates cytokine and chemokine expression, which subsequently protects neurons from oxygen-glucose deprivation (OGD). Because excitotoxicity and cell death following ischemia can be enhanced by excessive Ca²⁺ influx, application of the AQ protein likely confers neuroprotection via its calcium-binding capabilities.

4. Scientific Evidence by Area of Use

4.1 Cognitive Function and Memory (Human/Clinical Evidence)

The entire body of published human clinical evidence for apoaequorin's effects on cognition rests on a single manufacturer-sponsored trial known as the Madison Memory Study.

The Madison Memory Study (Moran et al., 2016): The Madison Memory Study was a randomized trial that included 218 community-dwelling adults aged 40 to 91 with self-reported memory concerns who were treated with either apoaequorin or placebo for 90 days. The study was designed as a randomized, double-blind, placebo-controlled trial. Cognition was assessed using the CogState International Shopping List and ISL-Delayed Recall instruments at baseline and at days 8, 30, 60, and 90.

A single trial of oral apoaequorin in patients with memory problems found no overall differences in changes in measures of verbal learning in comparison to placebo, but slightly greater improvements were reported in a subset of patients with normal cognitive test values at baseline. The apoaequorin group showed a statistically significant 10–16% improvement (p<0.001) in verbal learning and working memory at the end of the 90 days, while the control group showed a more modest (3–8%) change that was not significant (p>0.2). However, these results were derived from subgroup analyses rather than the primary intention-to-treat population. The Madison Memory Study, involving 218 participants, evaluated Prevagen's effects but yielded inconsistent results. Critics argue the study's positive findings resulted from selective post-hoc analyses, increasing the likelihood of random errors.

Human data on apoaequorin are limited to small, company-sponsored trials that do not meet expected scientific standards. There is very little clinical research on this compound other than information provided by the manufacturer of Prevagen®, which includes one manufacturer-affiliated randomized controlled trial (RCT) that identified statistically significant improvement in verbal learning and recall.

Overall clinical evidence strength: There are no high-quality studies demonstrating that apoaequorin is effective for improving memory loss or for treating any health condition. The single published trial was entirely manufacturer-sponsored, relied on post-hoc subgroup analyses to claim positive results, and failed to demonstrate benefit in the primary study population as a whole. No independent replication has been published.

4.2 Sleep Quality

An open-label sleep quality study with 55 healthy adults was carried out by the manufacturer. After 90 days, subjects reported an average increase in sleep time by 40 minutes per night, fewer numbers of waking events (from 3.56 to 1.81 times), and an improvement in self-reported quality of sleep. While there is rationale for better cognition with improved sleep, it is unclear how much of these changes were due to placebo effects.

An open-label sleep quality study, also carried out by a manufacturer, reported increased sleep time and quality of sleep with an apoaequorin supplement. This study lacked a placebo control group. The trial did not directly compare the apoaequorin group with the control, thus failing to produce any evidence that apoaequorin worked better than placebo.

Evidence strength: Extremely weak. The sole evidence derives from a single open-label, uncontrolled, manufacturer-conducted study. Placebo effect cannot be excluded.

4.3 Neuroprotection Against Ischemia (Preclinical Evidence Only)

Calcium is pivotal in a variety of neuronal signaling cascades; however, during ischemia, excess calcium influx can trigger excitotoxic cell death. Calcium-binding proteins help neurons regulate/buffer intracellular calcium levels during ischemia.

A 2013 PLoS ONE study (Detert et al.) examined direct intra-hippocampal infusion of apoaequorin in a rat brain slice model of ischemia. The study used an in vitro rat brain slice preparation to test the hypothesis that an intra-hippocampal infusion of apoaequorin (the calcium-binding component of aequorin) protects neurons from ischemic cell death. Bilaterally cannulated rats received an apoaequorin infusion in one hemisphere and vehicle control in the other. Hippocampal slices were then subjected to 5 minutes of oxygen-glucose deprivation (OGD), and cell death was assayed by trypan blue exclusion. The study demonstrates that apoaequorin is neuroprotective in a time- and dose-dependent manner when administered prior to ischemic injury. Intra-hippocampal infusion of either 1% or 4% AQ resulted in significantly fewer dead or dying neurons as compared to animals infused with control. This neuroprotection was time-dependent, in that it took up to 1 or 2 days to develop and it subsided by 3 to 5 days.

Critical limitation: These neuroprotective effects were observed only when apoaequorin was infused directly into the hippocampus, not via oral administration. Protection from ischemic cell death is seen, though only when applied directly onto neural tissue, not delivered orally. No human data exist on neuroprotection.

4.4 Age-Related Cognitive Deficits (Animal Studies)

A 2020 study published in Brain and Behavior (Ehlers et al.) assessed intrahippocampal AQ infusion on fear memory in adult and aged rats. Two experiments were conducted to evaluate the impact of direct intrahippocampal infusion of apoaequorin on trace and context fear memory. Results suggest that intrahippocampal infusion of AQ may reverse aging-related deficits in hippocampus-dependent context fear memory.

Evidence strength: Preclinical only. All positive findings from animal research involve direct brain infusion rather than oral supplementation, which limits their translatability to human oral supplementation.

4.5 Amyotrophic Lateral Sclerosis (ALS)

Apoaequorin has been used off-label in patients with amyotrophic lateral sclerosis and multiple sclerosis. The evidence for ALS is limited to a single case series. Payne (2009) reported an experimental regimen targeting the ependyma that slows disease progression in four patients with amyotrophic lateral sclerosis, published in Medical Hypotheses. Some reports suggest that taking 20 mg of apoaequorin every 2–3 waking hours along with other drugs and supplements might slow the progression of ALS. Insufficient data exists on whether it slows progression of amyotrophic lateral sclerosis in humans.

Evidence strength: Extremely weak. A four-patient anecdotal report in a hypothesis-generating journal provides no reliable evidence of efficacy.

4.6 Canine Cognitive Dysfunction (Animal Study)

A study compared 24 dogs treated with either a 5-mg or 10-mg dose of apoaequorin or with 1 mg/kg selegiline (Anipryl), an approved treatment for cognitive dysfunction. The group administered 10-mg apoaequorin showed superior performance to the animals administered selegiline on both tasks. These results suggest the calcium-binding protein apoaequorin may have beneficial effects in treating cognitive dysfunction in aged beagle dogs and that apoaequorin is at least as beneficial as selegiline.

Evidence strength: Preclinical/animal. Results in dogs are not directly translatable to human efficacy, particularly given known bioavailability limitations.

5. Body Systems and Health Areas Associated with Apoaequorin

Central nervous system / cognitive health: The primary claimed application. Proposed to support memory, verbal learning, and working memory in aging adults via calcium regulation in neuronal cells.
Neurological protection: Apoaequorin has been shown in laboratory studies to regulate levels of intracellular calcium in neuronal cells and to provide protection against ischemic cell death.
Sleep: Investigated in a single manufacturer-sponsored open-label study with self-reported improvements in sleep duration and quality.
Neurodegenerative disease: Apoaequorin has been proposed for use in combination products for treatment of amyotrophic lateral sclerosis. Apoaequorin has also been studied as a possible treatment for ALS. Additionally, it has been used off-label in multiple sclerosis patients, though controlled evidence is absent.

6. Dosage Forms and Doses Used in Studies

Prevagen is a daily capsule or tablet that comes in three strengths: 10, 20, and 40 milligrams of apoaequorin.

Cognitive/memory studies (human): The dose used in the randomized clinical trial was 10 mg daily, deemed safe by the manufacturer that ran the trial. The duration of supplementation in this study was 90 days.
ALS off-label use: ALS patients took 20 mg every 2–3 hours while they were awake (up to approximately 200 mg daily).
Sleep quality study: Early research shows that taking 10 mg of apoaequorin (Prevagen, Quincy Bioscience) daily for 90 days might increase sleep time by around 30–40 minutes per night, cut nighttime awakenings by 50%, and improve sleep quality in over 90% of people with this regimen. (These results are from a manufacturer-sponsored open-label study without a placebo control.)
No established recommended dose: There is no established recommended dose for taking apoaequorin.

7. Safety Considerations

General Tolerability

Side effects were not reported in the few prospective studies that have been published. Apoaequorin is considered generally safe and without major adverse effects. In the human studies that have been published, there were no reports of serum enzyme elevations occurring during therapy and no mention of serious adverse events or hepatotoxicity.

Adverse Events Reported in Pharmacovigilance Data

The most common adverse events reported were headache (18.76%), followed by dizziness (7.54%), nausea (6.80%), and hypertension (3.68%). All serious adverse events were judged by the physicians to be associated with pre-existing chronic conditions or unrelated to Prevagen® use. These data derive from the manufacturer's own review of consumer-reported adverse events submitted in the context of a subsequently withdrawn GRAS notification.

The GRAS notice stated that there had been more than 2,200 instances of user-reported adverse health effects from the chemical's use as a dietary supplement. The reports, primarily consumer complaints, describe memory impairment, anxiety, hypertension, headaches, dizziness, insomnia, nausea, and diarrhea. The company identified 26 reports as "serious adverse events," mainly neurological and cardiovascular problems. Despite these reports, two physicians hired by the law firm that filed the notice for the company concluded that apoaequorin was likely not the cause of the serious adverse events.

Within the PatientsLikeMe community, two multiple sclerosis patients who were taking apoaequorin reported serious adverse events; one described hypotension severe enough to cause a coma, and the other described depression with suicidal thoughts. Causality in these cases was not established.

The company also failed to report almost 1,000 adverse events associated with the product, including seizures, strokes, and heart arrhythmias. Note: adverse events associated with the use of a product do not necessarily mean the adverse event was caused by the product.

Hepatotoxicity

Apoaequorin has not been associated with serum enzyme elevations during therapy nor with clinically apparent liver injury. Likelihood score: E (unlikely cause of clinically apparent liver injury).

Allergy

Allergic reactions can occur with proteins taken orally but have not been reported with apoaequorin.

Preclinical Toxicology

Apoaequorin administration to rats at doses up to 667 mg/kg/day for 90 days did not reveal any adverse effects. The No Observed-Adverse-Effect Level (NOAEL) for apoaequorin was determined as 667 mg/kg body weight/day, the highest dose tested. The human equivalent dose is 106.67 mg/kg, which is approximately 640 times what an average person (weighing 60 kg) would take, assuming he or she takes 1 pill daily.

Drug Interactions

The risk for serious drug interactions with apoaequorin is not known. No interaction studies have been published in peer-reviewed literature.

Regulatory Status and FDA Actions

Apoaequorin has not been approved by the FDA as therapy of memory loss or neurologic illnesses. On September 2, 2014, Quincy Bioscience submitted a notice to FDA that apoaequorin is GRAS (generally recognized as safe), but withdrew the notice on October 21, 2015, at which point FDA ceased to evaluate the notice. The FDA warned Quincy that its unapproved and synthetic version of apoaequorin should be regulated and marketed as a drug, not as a supplement.

FTC and Legal Actions

The FTC and New York State AG charged the marketers of the dietary supplement Prevagen with making false and unsubstantiated claims that the product improves memory, provides cognitive benefits, and is "clinically shown" to work. An injunction filed December 6, 2024, the long-awaited ruling on charges first filed by the Federal Trade Commission and Attorney General of New York in 2017, forbids Quincy from making claims that Prevagen-branded products can improve memory or cognition, that Prevagen can show results within 90 days, and that Prevagen is "clinically proven" to work.

On March 11, 2024, the jury concluded that none of these statements were supported by reliable scientific evidence. The Court affirms its Judgment and clarifies that its injunction forbidding defendants from using the eight marketing statements in connection with the promotion of Prevagen takes effect forthwith and applies nationally wherever Prevagen is marketed. The injunction does not constitute a product ban; Quincy Bioscience has indicated it intends to appeal the decision.

8. Summary of Evidence Quality

Apoaequorin occupies an unusual position in the dietary supplement landscape. Its biological activity as a calcium-binding protein is well established in the context of research biochemistry and molecular imaging, where it has been a foundational tool for decades. However, its transition to an orally administered supplement faces a fundamental mechanistic obstacle that remains unresolved: there is strong evidence suggesting that apoaequorin does not survive digestion in the gut or cross the blood-brain barrier, so is unlikely to have any effect on the brain.

The sole published human randomized controlled trial failed its primary endpoint and demonstrated statistically significant effects only in post-hoc subgroup analyses. In the one study Quincy conducted to test apoaequorin's effectiveness in reducing memory loss related to aging, there were no statistically meaningful results in the overall population. There are no ongoing studies or trials of apoaequorin. Preclinical evidence of neuroprotection and memory modulation, while scientifically intriguing, was generated using direct intra-cerebral infusion rather than oral administration, and cannot be extrapolated to support the efficacy of an oral supplement. A group of scientists, doctors, scholars, and policy experts brought together by the AARP said it could not recommend any ingredient or supplement marketed for brain health after reviewing the available research. The group concluded that a healthy diet was the best way to get brain-boosting nutrients.

References

Health Conditions

Health conditions that Apoaequorin may help support.

No conditions available.

Body Systems

Body systems that Apoaequorin may help support.

No body systems available.